We are live on ! Find out more
WST icon

West Pharmaceutical

406 hedge funds and large institutions have $9.57B invested in West Pharmaceutical in 2019 Q3 according to their latest regulatory filings, with 64 funds opening new positions, 143 increasing their positions, 134 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more funds holding in top 10

Funds holding in top 10: 25 (+3)

100% more first-time investments, than exits

New positions opened: 64 | Existing positions closed: 32

12% more capital invested

Capital invested by funds: $8.52B → $9.57B (+$1.05B)

9% more funds holding

Funds holding: 374406 (+32)

7% more repeat investments, than reductions

Existing positions increased: 143 | Existing positions reduced: 134

0.89% less ownership

Funds ownership: 92.4%91.52% (-0.89%)

85% less call options, than puts

Call options by funds: $7.21M | Put options by funds: $47.8M

Holders
406
Holders Change
+32
Holders Change %
+8.56%
% of All Funds
8.9%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.11%
New
64
Increased
143
Reduced
134
Closed
32
Calls
$7.21M
Puts
$47.8M
Net Calls
-$40.5M
Net Calls Change
+$3.68M
Name Holding Trade Value Shares
Change
Change in
Stake
HA
226
Harfst & Associates
Wyoming
$855K +$6.61K +48 +0.8%
Fiera Capital (Canada)
227
Fiera Capital (Canada)
Quebec, Canada
$851K
SG Americas Securities
228
SG Americas Securities
New York
$851K +$31.9K +232 +4%
HF
229
HRT Financial
New York
$850K +$826K +6,000 New
BCM
230
Bayesian Capital Management
New York
$829K +$805K +5,845 New
LTFS
231
Ladenburg Thalmann Financial Services
Florida
$806K +$229K +1,665 +41%
CAM
232
Congress Asset Management
Massachusetts
$804K +$781K +5,669 New
WA
233
Wheatland Advisors
Pennsylvania
$794K
TI
234
Trexquant Investment
Connecticut
$750K +$271K +1,966 +59%
Wolverine Trading
235
Wolverine Trading
Illinois
$749K +$108K +788 +17%
ZB
236
Zions Bancorporation
Utah
$745K +$1.51K +11 +0.2%
MML Investors Services
237
MML Investors Services
Massachusetts
$736K +$44.6K +324 +7%
HighTower Advisors
238
HighTower Advisors
Illinois
$729K +$7.3K +53 +1%
FRM
239
Fox Run Management
Connecticut
$728K +$707K +5,136 New
MAM
240
Martingale Asset Management
Massachusetts
$725K +$331K +2,404 +89%
GCP
241
GSA Capital Partners
United Kingdom
$710K +$282K +2,045 +69%
QT
242
Quantamental Technologies
New York
$702K +$131K +954 +24%
ECM
243
Evergreen Capital Management
Washington
$699K
RCM
244
Riverhead Capital Management
Delaware
$696K
SCM
245
Shelton Capital Management
Colorado
$694K -$18.9K -137 -3%
NIPH
246
NN Investment Partners Holdings
Netherlands
$681K +$661K +4,800 New
Zurich Cantonal Bank
247
Zurich Cantonal Bank
Switzerland
$652K +$20.1K +146 +3%
Allianz Asset Management
248
Allianz Asset Management
Germany
$634K +$46.4K +337 +8%
ACI
249
AMP Capital Investors
Australia
$634K +$363K +2,634 +141%
QCM
250
Quantinno Capital Management
New York
$631K -$39.9K -290 -6%

WST Hedge Fund Activity: Q3 2019 in Review

406 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q3 2019, worth a combined $9.57B — up 12% from $8.52B a quarter earlier.

Buyers outnumbered sellers: 64 funds opened new WST positions and 32 closed out — a net gain of 32 holders — while 143 added to existing stakes and 134 trimmed.

The largest buyer was Millennium Management, adding an estimated $71.8M. The largest seller was AllianceBernstein, cutting an estimated $118M.

  • 406 institutional investors held West Pharmaceutical (WST) as of Q3 2019, up from 374 in Q2 2019.
  • Funds reported $9.57B of West Pharmaceutical stock for Q3 2019, up 12% quarter-over-quarter.
  • 64 funds opened new West Pharmaceutical positions in Q3 2019 and 32 closed out, a net change of +32 holders.
  • The largest West Pharmaceutical buyer in Q3 2019 was Millennium Management, an estimated $71.8M added.
  • The largest West Pharmaceutical seller in Q3 2019 was AllianceBernstein, an estimated $118M sold.

Based on aggregated 13F filings for Q3 2019.